人参皂苷Rg1在肝损伤向肝纤维化动态进展中的保护作用：一项临床前的荟萃分析
Protective role of ginsenoside Rg1 in the dynamic progression of liver injury to fibrosis: a preclinical meta-analysis.
作者信息
Dan Lijuan, Li Xiuyan, Chen Shuanglan, You Xiaojie, Wang Dong, Wang Tianyuan, Li Jia, Liu Wenping, Mu Jie, Feng Quansheng
机构信息
School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
出版信息
Front Pharmacol. 2025 Jan 28;16:1512184. doi: 10.3389/fphar.2025.1512184. eCollection 2025.
BACKGROUND
The pathological progression from liver injury to fibrosis is a hallmark of liver disease, with no effective strategies to halt this transition. Ginsenoside Rg1 has demonstrated a range of hepatoprotective properties; however, systematic preclinical evidence supporting its therapeutic potential for liver injury and fibrosis remains limited. Purpose. This study evaluated the efficacy and underlying mechanisms of ginsenoside Rg1 in animal models of liver injury and fibrosis, and providing a basis for future clinical investigation.
METHODS
A systematic review was conducted on preclinical studies published in PubMed, Web of Science, and Embase databases up to 1 August 2024, adhereing to rigorous quality standards. The methodological quality was assessed using SYRCLE's risk of bias tool. Meta-analysis and subgroup analysis were performed using Revman 5.4 software, while publication bias was evaluated through funnel plots and Egger's test in STATA 15.0 software. Additionally, a time-dose interval curve was utilized to assess the dose-response relationship and identify the effective dose of ginsenoside Rg1 for treating liver injury and fibrosis.
RESULTS
Twenty-four trials involving 423 animals were included. The findings indicated that ginsenoside Rg1 significantly improved liver function markers (ALT and AST), reduced pathological indicators associated with liver injury and fibrosis, and lowered liver fibrosis-related markers (α-SMA, HYP, and PCIII). Furthermore, it exhibited beneficial effects on mechanistic indicators of inflammation, oxidative stress, and apoptosis, compared to the control group ( < 0.05). Time-dose interval analysis revealed that the effective dose range of ginsenoside Rg1 was between 4 and 800 mg/kg/d.
CONCLUSION
Rg1 at a dose of 4-800 mg/kg/d mitigates the progression of liver injury to fibrosis via anti-inflammatory, antioxidative, and anti-apoptotic pathways.
SYSTEMATIC REVIEW REGISTRATION
https://www.crd.york.ac.uk/PROSPERO/, identifier CRD 42024557878.
背景
从肝损伤到肝纤维化的病理进展是肝脏疾病的一个标志，目前尚无有效的策略来阻止这种转变。人参皂苷Rg1已显示出一系列肝脏保护特性；然而，支持其对肝损伤和肝纤维化治疗潜力的系统临床前证据仍然有限。目的。本研究评估了人参皂苷Rg1在肝损伤和肝纤维化动物模型中的疗效及潜在机制，为未来的临床研究提供依据。
方法
对截至2024年8月1日发表在PubMed、科学网和Embase数据库上的临床前研究进行系统评价，遵循严格的质量标准。使用SYRCLE的偏倚风险工具评估方法学质量。使用Revman 5.4软件进行荟萃分析和亚组分析，同时通过漏斗图和STATA 15.0软件中的Egger检验评估发表偏倚。此外，利用时间-剂量间隔曲线评估剂量反应关系，并确定人参皂苷Rg1治疗肝损伤和肝纤维化的有效剂量。
结果
纳入了涉及423只动物的24项试验。结果表明，人参皂苷Rg1显著改善肝功能指标（ALT和AST），降低与肝损伤和肝纤维化相关的病理指标，并降低肝纤维化相关标志物（α-SMA、HYP和PCIII）。此外，与对照组相比，它对炎症、氧化应激和细胞凋亡的机制指标表现出有益作用（<0.05）。时间-剂量间隔分析显示，人参皂苷Rg1的有效剂量范围为4至800mg/kg/d。
结论
剂量为4-800mg/kg/d的Rg1通过抗炎、抗氧化和抗凋亡途径减轻肝损伤向肝纤维化的进展。
系统评价注册
https://www.crd.york.ac.uk/PROSPERO/，标识符CRD 42024557878。
Zotero 插件